Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2019 1
2020 2
2021 4
2022 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem.
Sertić Z, Lucijanić M, Bašić-Kinda S, Serventi Seiwerth R, Periša V, Sertić D, Coha B, Pulanić D, Perić Z, Desnica L, Mikulić M, Vodanović M, Radman-Livaja I, Šegulja D, Rogić D, Valković T, Aurer I, Duraković N. Sertić Z, et al. Among authors: segulja d. Biomedicines. 2022 Nov 11;10(11):2892. doi: 10.3390/biomedicines10112892. Biomedicines. 2022. PMID: 36428459 Free PMC article.
Analytical validation of 39 clinical chemistry tests and 17 immunoassays on the Alinity analytical system.
Lapić I, Šegulja D, Dukić K, Bogić A, Lončar Vrančić A, Komljenović S, Šparakl T, Grdiša Teodorović K, Cigula Kurajica V, Baršić Lapić I, Kralik Oguić S, Kozmar A, Vogrinc Ž, Rogić D. Lapić I, et al. Among authors: segulja d. Scand J Clin Lab Invest. 2022 May;82(3):199-209. doi: 10.1080/00365513.2022.2056856. Epub 2022 Apr 2. Scand J Clin Lab Invest. 2022. PMID: 35373677
Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study.
Habek M, Jakob Brecl G, Bašić Kes V, Rogić D, Barun B, Gabelić T, Emeršič A, Horvat Ledinek A, Grbić N, Lapić I, Šegulja D, Đurić K, Adamec I, Krbot Skorić M. Habek M, et al. Among authors: segulja d. J Neuroimmunol. 2021 Oct 15;359:577696. doi: 10.1016/j.jneuroim.2021.577696. Epub 2021 Aug 16. J Neuroimmunol. 2021. PMID: 34418815 Free PMC article.
14 results